Intriguingly, high expression of IGF2BP3 was associated with a poor prognosis not only in hematologic malignances but also in other solid tumors, such as colon cancer, uveal melanoma, mesothelioma, lung adenocarcinoma, glioma, renal papillary cell carcinoma, and renal clear cell carcinoma (Supplementary Fig. 3a–h). This evidence concerns the gene IGF2BP3 and lung adenocarcinoma.